Spread Betting

Types of genes changed by CR BioMarker s strategy is to search for the genes most critically involved in the aging process by exploring the changes in gene expression caused by caloric restriction in various tissues (liver, heart, brain and muscle) in mice, monkeys and humans throughout their life span, and to discover what gene changes occur when CR is started at different ages, and carried on for varying periods of time. BioMarker scientists are looking for changes in key regulatory genes that trigger secondary gene changes. They are looking for changes that occur in multiple tissue types very early in the crossover from the aging gene expression profile to the anti-aging gene expression profile. financial spread trading

The changes in gene expression caused by caloric restriction were separated into defined functional classes for further study. These include genes involved in carbohydrate, fat and protein metabolism; signal transduction for cell growth and proliferation, cell suicide (apoptosis); and the production of insulin, growth hormone and insulin-like growth factor-1; cellular protection against oxidative free radicals and other types of stress inducers; xenobiotic metabolism involved in detoxification of chemicals; and inflammation. nfl betting spread

Among the metabolic genes that changed with CR were genes that indicate CR enhances the breakdown and turnover of whole-body protein. These changes should drive protein renewal throughout the body. Some of the genes reduced the enzymatic capacity for lipid biosynthesis and metabolism, which may account for the decreases in serum triglyceride and cholesterol levels in CR animals. [13] commodity spread trading

Biomarker Launches Series A Fundraising Efforts Annual Super Sale - Time is running out to enjoy the lowest prices of the year

Biomarker Launches Series A Fundraising Efforts August 1, 2003 Biomarker Pharmaceuticals, Inc. is one of the first companies to apply a scientifically validated and proprietary approach to develop safe and effective therapeutics to retard aging. The Company has formally started efforts to raise new funds to finance needed development efforts leading to first clinical trials. The Company has engaged Satwik Venture Capital Partners II, LLC ( SVC Partners ) a San Jose based investment and venture capital firm, to assist in qualifying investors and to manage the investment process. betting exchange spread

We are excited to be at this critical juncture and looking forward to successfully raising outside investor capital to take the Company to the next stage. SVC Partners is noted for raising capital for early stage firms such as ours and has a well-developed process for working with both qualified individual investors and institutions. They will lead the fundraising and management efforts on our behalf, thereby allowing us to focus on achieving important milestones, stated Xi Zhao-Wilson, Biomarker CEO. advanced commodity spread

Over the past 3 years, our partners have raised over $120M for numerous emerging technology firms plus managed investor funds through our group of specialized investment entities. We think that Biomarker represents the type of breakthrough firm that will be very attractive to both qualified individual investors and institutions, said Paul Getty, Managing Member of SVC Partners. online spread betting

About Biomarker Biomarker intends to introduce a new class of therapeutics that is based on recent advances in understanding how genes control the aging process, and how therapeutic interventions can be developed to slow aging, prevent age-related diseases and extend maximum lifespan. The Company uses a patented method for developing therapeutics for slowing aging and treating a broad range of age-related diseases. This method has been shown to be the only reliable approach that truly extends lifespan. Animals placed on calorie restricted (CR) diets experience an extension of maximum lifespan of up to 80% and a remarkable reduction in the incidence of diseases that normally accompany aging. BioMarker is applying molecular genetics to animal models of CR, in order to discover new therapeutics, which will extend youth, vigor, and life span. stock spread trading

BioMarker s uses DNA microarrays (gene chips) to measure gene expression in the tissues of normally aging mice, monkeys and humans as well as in life extension models such as CR. The Company has discovered the gene expression changes characteristic of aging, which are reversed in long-living CR animals. The gene changes are also associated with the remarkable broad-spectrum disease-preventative properties associated with CR. The Company is developing pharmaceuticals, nutraceuticals, and other therapies that mimic these changes. betting horse racing spread

The rationale for this strategy is that any therapy that closely mimics the gene expression effects of therapies that slow aging, prevents age-related diseases and extends maximum life span in animals will likely have the same effects in humans, without the necessity of perpetual hunger. complete guide spread trading

BioMarker Pharmaceuticals, Inc. is a California corporation established in June 2002. The headquarters are located at 900 E. Hamilton Ave., Suite 100, Campbell, CA 95008, and the research facilities are in Riverside, California. See www.biomarkerinc.com for more information about Biomarker. sport spread betting

About Satwik Venture Capital Partners SVC Partners mission is to provide its investors with exceptional returns by investing in high-tech companies that focus on breakthrough technology. The firm invests in companies where it can add strategic value such as joint strategic planning, operational management and leadership, and introductions to customers and potential employees. SVC Partners brings technology, alliances, finances, people placement, and business development together by using a strong network of successful technologists and executives in Silicon Valley, and reputed financial executives and institutions worldwide. low spread forex trading

Satwik Venture Capital Partners II, LLC is a Delaware LLC with its main offices located at 100 Century Center Court, Suite 503, San Jose, CA 95112. Potential Investors looking for more information regarding the offering should contact either Paul Getty (pgetty@satwik.com; 408-392-0073) or Dinesh Gupta (dgupta@satwik.com; 408-392-0072) at SVC Partners directly. More information on the SVC Partners and its related entities may also be found at www.satwik.com. trading spread and seasonals

THIS NOTICE DOES NOT CONSTITUTE EITHER AN OFFER TO SELL OR AN OFFER TO PURCHASE SECURITIES BioMarker Pharmaceuticals, Inc. 900 E. Hamilton Avenue, Suite 100, Campbell, CA 95008 Phone: 408.257.2000 Fax: 408.356.6661 Web site: www.biomarkerinc.com Email: info@biomarkerinc.com, press@biomarkerinc.com. Free Magazine Subscribe to Life Extension Magazine | Receive the 112-page Life Extension magazine that delivers up-to-date coverage of the latest scientific and medical breakthroughs from around the world. betting guide insider sports

Europe Threatening To Ban Dietary Supplements dietary, supplements, diet, supplement, europe, john hammel, health LE Magazine: Europe Threatening To Ban Dietary Supplements - Report by By John C. Hammell, President International Advocates for Health Freedom.

International Assistance Needed To Stop Draconian EU Vitamin Laws By John C. Hammell, President International Advocates for Health Freedom http://www.iahf.com Poster for the Health Freedom Movement Currently under consideration in Europe is legislation that will severely limit a consumer right to choose and use supplements. This restrictive legislation is the first major step towards the adoption of global standards for the regulation of dietary supplements, as is being worked on at the UN Codex Alimentarius Commission. Since the U.S. is part of this process and is a member of the World Trade Organization, the U.S. could be forced to harmonize its vitamin laws with these new, highly restrictive international standards. arbitrage spread trading

In an effort to stop this punitive legislation, the Alliance for Natural Health (ANH), an organization based in England, is planning to file an emergency lawsuit on behalf of consumers, vitamin companies and health food stores to overturn the European Union (EU) Food Supplements Directive, which became law on June 10, 2002. The Food Supplements Directive (FDS), currently concerns itself only with vitamins and minerals. However, by the year 2007 the European Union (EU) will be obliged to provide detailed proposals to expand the law to cover all other types of nutrients. Eventually this will force vitamin companies to reformulate their most important supplements. Although the 13 key vitamins would be permitted, the Directive excludes the most bioavailable forms of vitamin complexes. For example, The Food Supplement Directive bans any chelated or other organically complexed mineral forms such as selenomethionine. Additionally, it will only allow the alpha-tocopherols of Vitamin E but excludes the complete tocopherol range as found in nature (including the gamma-tocopherols), which are far more effective as antioxidants than the simpler alpha-tocopherol group. Research has proven that many vitamins and minerals are most bioavailable when in the forms found in nature. Unless the current Directive is overturned, many Life Extension products will be banned, and the Foundation will be forced to either cease selling particular products in Europe or will be forced to reformulate their scientifically-balanced products. betting spread successful

Replacing them would be vitamins that are less bio-available, potentially more toxic and better suited to the pharmaceutical industry affiliated supplement companies. In other cases, entire minerals such as boron, sulphur and vandadium would have to be removed as they would not be allowed under the new EU law. If this law is not overturned in July 2003 then it will become the national law of all European Union member states including England, Ireland, Netherlands and Sweden, which currently have liberal vitamin laws similar to those of the United States. Along with the Food Supplements Directive, is the additional threat of the Traditional Herbal Medicinal Products Directive which would impose medicinal law on herbs and other so-called borderline supplements. Both of these Directives would severely limit any chance for individuals to oversee their heath as they so choose. college football betting

TAKING IT TO THE STREETS Veteran health freedom advocate Clinton Ray Miller (left) and Bonnie Miller advise ANH Attorney David Hinde on defending vitamin access world wide. On June 15th, the UK-based Health Freedom Movement (HFM) (http://www. .com), a consortium of more than 700 health freedom organizations, will be holding a street march and health freedom rally in central London in opposition to England harmonizing their vitamin law to the Food Supplements Directive. The march will go from Hyde Park to Trafalgar Square. Lynne McTaggart of HFM told me in an interview that she hopes to carry a message to the government and to the EU that the FSD is totally unacceptable. She also hopes to generate donations for the Alliance for Natural Health, a non-profit organization seeking ways to change, reshape or revoke laws affecting dietary supplement consumers, practitioners and manufacturers in Europe. As publisher of What Doctors Don Tell You (http://www.wddty.co.co.uk), the UK leading alternative medical newsletter, McTaggart, who is in constant contact with alternative practitioners, supplement manufacturers and consumers, is painfully aware of what is at stake with this pending legislation. She wants American vitamin companies and consumers to be aware that, (ill we, along with future generations be deprived of access to the most innovative dietary supplements currently on the market including many of the Life Extension Foundation products Will the Foundation be forced to reformulate Life Extension Mix by removing all the most bio-available, effective and natural-state nutrients Will the Foundation be blocked from selling life-saving products due to future harmonization to a grossly restrictive international standard We stand at a crossroad he fate of this global industry is literally in all of our hands right now. We sink, or swim, together. This is the battle for The Dietary Supplement Health and Education Act (DSHEA) all over again, but this time on a world stage. We can be negatively impacted here via the mechanisms of globalization unless we actively assist our international allies. Those who think DSHEA posed the ultimate bulwark against the Pharma Cartel are sadly mistaken. betting point spread on nfl

Summary of key European legislation affecting dietary supplements Food Supplements Directive (FSD) Pharmaceuticals Directive (PD) Traditional Herbal Medicinal Products Directive (THMPD) Status Passed into EU law 10 June 2002 First Reading 23 October 2002 First Reading 21 November 2002 Impact Limits ingredients (nutrient sources) and maximum dosages. Framework structure; only applies to vitamins and minerals at present, will cover other nutrients in future. Full impact will not be felt until 2005 - 2009. Is likely to omit 285 nutrient sources that are currently used in Europe. Improved prospects for trade between European countries. betting point spread

All dietary supplements that are not controlled under FSD will be controlled under PD. A drugs regime would therefore apply and this would not be affordable for many non-pharmaceutical-owned supplement manufacturers. super bowl betting spread

A derogation of PD which allows fast-track legislation for eligible herbal products. The number of products caught will ultimately depend on PD definition of a medicine. Allows for improved labelling and quality control of medicinal herbs. betting fan football guide

Potential for improvements to Directive Can affect implementation in EU member states through national authorities. Can influence maximum permitted levels of nutrients. Consider challenging entire legality of directive. Can alter the definition of a medicine, as well as scope of directive, to ensure that most dietary supplements cannot fall under PD. Can positively exclude non-medicinal food supplements, herbs and cosmetics. spread betting uk

First Reading amendments allow for combinations of herbs and nutrients, but make ineligible herbs that have less than 10 years use in EU. Can promote amendments for Second Reading which allow traditional (e.g. 30-year) use from outside the EU with evidence from a competent authority. Summary of ANH achievements in 2002 Mounted Brussels and UK-based campaign which helped to almost block FSD s passage through Second (final) Reading in EU Parliament. betting betting fan football

Lobbied to ensure tabling of critical amendments on definition of a medicine, scope of directive and exclusions. All amendments successfully voted for at First Reading. Lobbied to help ensure major amendments were supported. Key amendment on non-EU traditional use was lost in pre-First Reading vote but successfully re-tabled by European Liberal Democrats at First Reading plenary. Although it again failed, it can be re-tabled at Second Reading. Source: Alliance for Natural Health Newsletter, March 2003. betting company germany in

Recently I spoke at the Vitality Vitamin Trade Show in England before a group of alternative medical practitioners and consumers who form the backbone of the growing European health freedom movement. My concern is that these latest directives threaten to force the creation of a draconian vitamin standard at the UN Codex Alimentarius Commission. What is especially troubling is that due to America membership in the Word Trade Organizatoin, the United States could be forced to harmonize its vitamin laws to this emerging restrictive international standard. ig index spread betting

Le Magazine, August 2003 - As We See It: Fda s Lethal Impediment

William Faloon The FDA stifles the discovery and availability of life-saving therapies by making the cost of getting them approved prohibitively expensive. The FDA is a major obstacle that prevents scientific findings from being translated into therapies to stave off age-related disease. Compared to the advancement of other technologies over the past 40 years, medicine has progressed the slowest as far as finding solutions for lethal diseases. Those in the medical establishment may debate this assertion, but the undeniable fact is that for most types of cancer and neurological diseases, there have been few substantive improvements in survival, let alone a cure. betting guide practical

image

Most of you remember attending funerals in the 1960s to 1970s of those who perished from cancer. If you thought the way I do, you would have been certain that a cure for cancer would have been found by year 2000. In fact, the propaganda being released by the cancer establishment at that time was that doctors were on the verge of eradicating most cancers. (This misguided optimism was primarily based on the premise that chemotherapy was the solution.) betting blogspot com site

When it comes to therapies designed to slow or reverse aging, the FDA still does not officially recognize aging as a disease process. That means when a company tries to gain approval to market an anti-aging therapy, it first has to overcome the hurdle of educating the FDA that aging is indeed a lethal disease. The new therapy then has to show sufficient efficacy to warrant approval. To date, no one has succeeded in convincing the FDA to approve an anti-aging drug. learn spread betting

In today s world of ever-expanding technological achievement, the fact that medicine remains bogged down in a regulatory quagmire is a disgrace. More than 6, 000 Americans die every single day, yet most of these deaths could be prevented if it were not for the strangulation of innovation caused by the FDA, State regulatory agencies, HMOs and apathetic physicians. football betting spread

In each issue of Life Extension magazine, we seek to uncover therapies that have shown efficacy in well-controlled studies, but have not yet been translated into conventional medical practice. We know our efforts have lengthened the lives of tens of thousands of Life Extension members, yet what we offer is only the tip of the iceberg when one looks at the many life-extending drugs that are denied to human beings in need. financial spread trading

Does Geron have an effective cancer vaccine Geron Corporation was originally established to develop anti-aging drugs. Their research, however, led them to discover a potentially effective cancer treatment. On March 18, 2003, Geron released the results of a study that an experimental cancer vaccine might be effective against all types of cancer. This bold announcement was based on a study published in the journal Cancer Gene Therapy (March 2003). nfl betting spread

What the public thinks about the FDA- Beginning May 8, 2003, Life Extension initiated an Internet poll on a website (www.deathclock.com) that has about 400, 000 new visitors each month. The people visiting this site are not part of any anti-FDA group, nor were they exposed to anti-FDA propaganda. These people were asked a simple question as to whether terminally ill cancer patients should have the right to any drug that might save their life. After 22, 506 votes were tabulated, here are the results: commodity spread trading

Terminally ill cancer patients

Should have access to any drug that might save their life: 89% Should only have access to drugs approved by the FDA: 11% We live in a constitutional republic where the people s wishes are supposed to be adhered to (as long as they don t infringe on the rights of others). If 89% of the American public thinks terminal cancer patients should have access to any drug that could save their life, then there is no reason for the law not to be changed to allow this. Companies that engaged in fraud could be prosecuted under consumer protection laws that already exist. The FDA could post its opinion about the safety and efficacy of purported cancer therapies on their website (www.fda.gov). The civil litigation risks to companies that knowingly sold bogus products would preclude large-scale unsavory activities that a minority of Americans fear. The greater fear Americans face is being diagnosed with cancer only to find out that a potential cure is too many years away to save their lives. betting exchange spread

Of interest was an identical poll on Life Extension s website in which 98% of people voted to allow cancer patients to have access to any drug that might save their life. This is not surprising considering health conscious people s animosity towards the FDA. advanced commodity spread

Geron s vaccine works in a relatively simple manner. It programs powerful dendritic immune cells to attack cells that express high levels of an enzyme called telomerase. It just so happens that 85% of human tumor cells overly express telomerase1 whereas normal healthy adult cells express very low and/or transient telomerase levels. Using telomerase as the target for dendritic cells, Geron s vaccine was shown to provoke a massive attack against prostate and kidney cancer cells as well as breast, melanoma and bladder cancer. online spread betting

Most cancer cells require high levels of telomerase to prevent them from undergoing a healthy cellular removal process called apoptosis (programmed cell death). The concept of attacking cells high in telomerase makes cancer cells particularly vulnerable, because if they try to hide from this vaccine by making less telomerase, then they will die via normal apoptosis. stock spread trading

There are 558, 000 people in the United States who will die of cancer over the next 12 months. Most of them know they are likely to die. We believe these cancer-stricken individuals should have the right to access any potentially effective therapy under the guidelines of an objective yet humanistic formal scientific protocol. While there is no assurance that Geron s new vaccine will cure cancer, we vehemently oppose the power given to the FDA to withhold this and other potential cancer therapies. betting horse racing spread

The cancer establishment maintains that only carefully controlled studies can establish safety and efficacy. This sounds reasonable and Life Extension agrees with this concept. The reality, however, is that the FDA s current clinical trial requirement has produced flawed data that enabled bad drugs to be approved while potentially effective drugs are denied.2, 3, 4 complete guide spread trading

It takes so long for a new drug to make it through the FDA approval process, that if Geron s new drug is effective, most cancer patients reading this column today will perish long before the vaccine ever became available. A real world example of this occurred with an anti-cancer agent for childhood leukemia called Vumon. This drug was first studied in 1972, but only attained FDA approval in 1992. sport spread betting

A Phase I study of Geron s telomerase vaccine is currently underway in patients with prostate cancer at Duke University in North Carolina. As described in previous issues of Life Extension magazine, there are two fundamental problems with Phase I studies. First of all, they usually mandate that cancer patients fail all proven therapies first. As has been repeatedly shown in published scientific studies, most so-called proven cancer therapies do not cure the disease. Since Phase I studies only test for safety, extremely small doses of the anti-cancer agent are used. This dooms virtually all the terminal cancer patients who participate in Phase I trials to certain death, but it does supply the FDA with the safety data it mandates. In other words, as long as the patient dies of their cancer and not the new drug, it is now permissible to move on from Phase I to Phase II studies where a potentially effective dose of the anti-cancer drug can be given. low spread forex trading

How the FDA perpetuates the cancer epidemic It is clear that the bureaucratic process is incredibly long for the approval of anti-cancer and other therapies used in the treatment of life-threatening diseases. To add insult to injury, the very same approval process has geographic boundaries that create inhumane and unacceptable delays for approval of a critical drug in one country that may be a few miles away from a country where the drug is already studied, reviewed and accepted. trading spread and seasonals

For example, it took years for Taxotere, one of the most impressive anti-cancer agents used to treat breast and prostate cancer, to finally gain FDA approval in the United States. This occurred despite hundreds of studies supporting its efficacy published in the European literature that were not acceptable to the FDA. betting guide insider sports

Ironically, now that Taxotere has gained FDA approval for the treatment of metastatic prostate cancer in the USA, countries such as Germany do not permit its use in the treatment of prostate cancer because no published papers on this subject have emanated from Germany. This becomes even more incredulous when one realizes that the pioneering research on Taxotere emanated from Germany s next-door neighbor France. The approval agencies such as the FDA here and its counterparts abroad are allowing bureaucratic ego, and perhaps economics, to interfere with the saving of life. Think about this! American and German physicians and scientists are engaged in a battle against a common enemy (cancer) while the respective regulatory agencies (those that approve the use of a drug) of each country use national borders to say yes or no to a live-saving drug or therapy. This is a violation of human rights within so-called civilized societies. People from all over the world should unite in protest to such atrocity. arbitrage spread trading

monebaggasse